tirzepatide poop does make you more Tirzepatide Side Effects: Common & Rare Reactions Explained The Link Between Tirzepatide and

It works by mimicking the action of Glucagon-like Peptide-1 (GLP-1), promoting insulin secretion, inhibiting glucagon secretion, and delaying gastric emptying, which helps control blood sugar levels and aids in weight loss

SGLT2 inhibitors and GLP-1 receptor agonists represent significant advances in the treatment of type 2 diabetes, but there are challenges in providing equitable access to these medicines.

Pfizer and Amgen are working on new GLP-1 shots designed to be taken once a month rather than weekly.

The first phase 3 retatrutide trial, TRIUMPH-4, top-line data announced today Retatrutide, a triple GLP-1,GIP, glucagon agonist studied in patients with obesity and osteoarthritis 28.7% weight loss at 68 weeks Reduced key cardiometabolic risk markers non-HDL cholesterol, triglycerides, and hsCRP Highest dose lowered systolic BP by 14 mmHg Reduced WOMAC pain scores by up to an average of 4.5 points (75.8%) and significantly improved measures of physical function GI side effects most common adverse event We now await 7 additional phase 3 trials in other obesity related comorbidities